What is CSL346 used for?

CSL346 is indicated for Relapsed or refractory B-cell non-Hodgkin lymphoma.

CSL346 is developed by CSL Behring.

What are the side effects of CSL346?

Common side effects include Infusion-related reactions, Neutropenia, Anemia.

Last reviewed 2026-04-23 · How we verify

CSL346

CSL Behring · Phase 2 active Biologic

CSL346 is a monoclonal antibody targeting the CD19 protein.

CSL346 is a monoclonal antibody targeting the CD19 protein. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.

At a glance

Generic name	CSL346
Sponsor	CSL Behring
Drug class	Monoclonal antibody
Target	CD19
Modality	Biologic
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

CSL346 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This can help to reduce the number of cancer cells in the body.

Approved indications

Relapsed or refractory B-cell non-Hodgkin lymphoma

Common side effects

Infusion-related reactions
Neutropenia
Anemia

Key clinical trials

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results